Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • About Us
  • Our Technology
  • Our Leadership
    • Board of Directors
    • Management Team
  • Investors & Media
  • Contact

NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine

By jgardnerMay 28, 2015Publications
NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine

GSK reports over 97% efficacy for their QS-21 containing Shingles vaccine in a large Phase III trial enrolling a total of 15,411 participants, with a mean follow up of 3.2 years.

Hz_su_NEJM_nejmoa1501184

Post navigation

Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination
Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine

Recent Posts

  • ADJUVANCE PARTICIPATES IN THE BIO CEO AND INVESTORS CONFERENCE
  • ADJUVANCE PRESENTS ITS 2021 POTENTIAL AND PLANS AT THE BIOTECH SHOWCASE
  • ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
  • ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme